Myeloid cell dynamics correlating with clinical outcomes of severe COVID-19 in Japan
Myeloid cell dynamics correlating with clinical outcomes of severe COVID-19 in Japan
复制标题
DOI：
10.1093/intimm/dxab005
复制
发表时间：
2021-02-04
影响因子：
4.4
通讯作者：
Takahashi, Yoshimasa
中科院分区：
文献类型：
--
作者：
Takano, Tomohiro;Matsumura, Takayuki;Takahashi, Yoshimasa
骨髓细胞区室扩大是2019年严重冠状病毒病（COVID-19）的标志。然而，在欧洲收集了有关骨髓细胞扩增的数据，那里的COVID-19死亡率高于包括日本在内的其他地区。因此，在死亡率低的地区，COVID-19诱导的骨髓细胞亚群的特征在很大程度上仍然未知。在这里，我们分析了骨髓源性抑制细胞（MDSC）亚群的细胞动力学，并使用日本COVID-19患者的血液样本检查了其中任何一种是否与疾病严重程度和预后相关。我们观察到多形核细胞（PMN）-MDSC（而不是其他MDSC亚群）在严重病例中短暂扩增，但在轻度或中度病例中则没有。与欧洲先前的研究相反，该亚组在严重病例的幸存者中选择性扩大，并在出院前消退，但在日本队列的非幸存者中未观察到这种短暂扩大。血浆细胞因子/趋化因子水平分析显示PMN-MDSC频率与IL-8水平呈正相关，表明IL-8参与了严重COVID-19发作后PMN-MDSC向外周血的募集。我们的数据表明，PMN-MDSC亚群的短暂扩增可改善临床结局。因此，这种骨髓细胞亚群可能是日本严重COVID-19病例的预后预测因子。
An expanded myeloid cell compartment is a hallmark of severe coronavirus disease 2019 (COVID-19). However, data regarding myeloid cell expansion have been collected in Europe, where the mortality rate by COVID-19 is greater than those in other regions including Japan. Thus, characteristics of COVID-19-induced myeloid cell subsets remain largely unknown in the regions with low mortality rates. Here, we analyzed cellular dynamics of myeloid-derived suppressor cell (MDSC) subsets and examined whether any of them correlate with disease severity and prognosis, using blood samples from Japanese COVID-19 patients. We observed that polymorphonuclear (PMN)-MDSCs, but not other MDSC subsets, transiently expanded in severe cases but not in mild or moderate cases. Contrary to previous studies in Europe, this subset selectively expanded in survivors of severe cases and subsided before discharge, but such transient expansion was not observed in non-survivors in Japanese cohort. Analysis of plasma cytokine/chemokine levels revealed positive correlation of PMN-MDSC frequencies with IL-8 levels, indicating the involvement of IL-8 on recruitment of PMN-MDSCs to peripheral blood following the onset of severe COVID-19. Our data indicate that transient expansion of the PMN-MDSC subset results in improved clinical outcome. Thus, this myeloid cell subset may be a predictor of prognosis in cases of severe COVID-19 in Japan.